Topic: autoimmune disease
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.
Novartis is picking up one clinical-stage and two preclinical NLRP3 antagonist programs in its acquisition of IFM Tre.
Polyneuron Pharmaceuticals has raised CHF 22.5 million to run a phase 1 trial in a rare autoimmune disease.
The deal gives Alexion rights to an anti-FcRn drug designed to have a longer half-life than rival assets in development at Argenx and UCB.
AbbVie and Principia are ending an autoimmunity-focused deal, with Principia regaining the rights to the immunoproteasome inhibitor program.
Scientists from CUNY and the Icahn School of Medicine have identified a possible mechanism of action for Biogen's MS drug Tecfidera.
Mallinckrodt and Transimmune hope to expand the applications of extracorporeal photopheresis to several new indications.
J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.
The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.
IFM Therapeutics is unveiling its second subsidiary, IFM Due, which will target the cGAS/STING pathway to treat inflammatory and autoimmune disease.